ArticleESMO real world data and digital oncology2024
Evaluation of machine learning methods for the retrospective detection of ovarian cancer recurrences from chemotherapy data.
Article in ESMO real world data and digital oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Explainable AI-based feature importance analysis for ovarian cancer classification with ensemble methods.Frontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cancer recurrences are poorly recorded within electronic health records around the world. This hinders research into the efficacy of cancer treatments. Currently, the retrospective identification of recurrence/progression diagnosis dates is achieved by staff who manually review patients' health records. This is expensive, time-consuming, and inefficient. Machine Learning models may expedite the review of health records and facilitate the assessment of alternative cancer therapies. Materials and methods: This paper evaluates the use of four machine learning models (random forests, conditional inference trees, decision trees, and logistic regression) in identifying proxy dates of epithelial ovarian cancer recurrence/progression from chemotherapy data, in 531 patients at Leeds Teaching Hospital Trust. Results: The random forest achieved the highest F1 score of 0.941 (95% confidence interval 0.916-0.968) when identifying recurrence events. Both the random forest and decision tree models' classifications closely conform to chart-reviewed time to next treatment, serving as a surrogate for recurrence-free survival. Additionally, all models reached an F1 score >0.940 when identifying patients whose cancer recurred/progressed. Conclusions: Our models proficiently identify both proxy dates for recurrence/progression diagnoses and patients whose cancer recurred/progressed. Considering the similar performance of the random forest and decision tree, model preference should be determined by the interpretability required to assist chart review and the ease of implementation into existing architecture.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.